Hormonal
Females have higher T2DM-related mortality rates than males globally, although males show a greater rate of increase in Disability-Adjusted Life Years (DALYs) over time.
Be aware that women face higher T2DM mortality rates than men globally. While men are seeing a faster rise in disease burden, women currently bear a heavier mortality toll. Both sexes should prioritize prevention, but women may need to be particularly vigilant about early diagnosis and management.
Increases in mortality were observed for both sexes, and females tended to have higher mortality rates per 100,000 persons... males had fewer T2DM DALYs than females, though a greater increase was observed among males.
Why this rating
Based on aggregate global data; sex differences are observed but the causal mechanisms are inferred from biological literature cited in the discussion.
Source
Sex differences and risk factors for diabetes mellitus - an international study from 193 countries
Devy L Elling et al. · Globalization and Health · 2018
DOI 10.1186/s12992-018-0437-7
More from this paper
- Low physical activity is a strong independent risk factor for Type 2 Diabetes Mellitus (T2DM) mortality, with an association magnitude of 2.4 per 100,000 persons, which is higher than dietary risks (1.4) and smoking (0.8).Moderate
- High Body Mass Index (BMI) is the leading risk factor for T2DM-related mortality globally, particularly in Low- and Middle-Income Countries, although trends in High-Income Countries showed a decrease between 2005 and 2015.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →